Equivalent Divigel Dose for Estradot 100mcg Patch
Start with Divigel 1.0 gram (1.0 mg estradiol) applied once daily, which is the approximate equivalent to your patient's current Estradot 100mcg patch used twice weekly.
Dosing Rationale
Your patient is currently receiving 100 mcg of estradiol twice weekly from the Estradot patch, totaling 200 mcg per week, or approximately 28.6 mcg per day on average.
Research directly comparing transdermal gel to patches demonstrates that 1.0 mg daily estradiol gel produces comparable serum estradiol levels to a 50 mcg/24h patch 1, 2. Since your patient is using a 100 mcg patch (twice the reference dose), the equivalent would be approximately 2.0 mg daily of gel. However, this calculation requires adjustment because:
- The 100 mcg patch is applied twice weekly (not daily), providing roughly 28.6 mcg/day average delivery
- A 50 mcg/24h patch delivers estradiol continuously, so "50 mcg" refers to daily delivery rate
- Your patient's patch likely delivers approximately 50 mcg per day when worn
Therefore, Divigel 1.0 gram daily (containing 1.0 mg estradiol) is the appropriate starting dose 3.
Titration Strategy
According to the FDA label, Divigel dosing should be individualized 3:
- Starting dose: 0.25 grams daily (can start here if concerned about over-replacement)
- Target dose range: Adjust up to maximum 1.25 grams daily as needed
- Monitoring: Assess symptom control and adjust dose accordingly
Given your patient is already on a moderate-to-high patch dose, starting at 1.0 gram daily is reasonable, with option to titrate to 0.75 grams if symptoms of excess estrogen develop, or up to 1.25 grams if vasomotor symptoms persist 3.
Important Clinical Considerations
Application technique matters significantly 3:
- Apply to upper thigh (alternating sides daily to avoid irritation)
- Application area should be 5 x 7 inches (two palm prints)
- Allow gel to dry before dressing
- Avoid washing application site for 1 hour
- Wash hands after application
Advantages of switching to gel 4, 5:
- Significantly lower rates of skin irritation (3.3% vs 46.7% with patches)
- No issues with patch detachment (which occurs in >50% of patch users, especially in warm climates)
- Better patient acceptability (96.4% vs 90.7%)
Progestogen requirement: If your patient has an intact uterus, ensure continued progestogen therapy to prevent endometrial hyperplasia 3.
Monitoring
While serum estradiol levels don't predict individual therapeutic response 3, they can be helpful if symptoms persist or if you suspect poor absorption. Research shows substantial interindividual variation in estradiol absorption from transdermal preparations, with approximately 25% of women on standard doses having subtherapeutic levels 6.
Clinical response to vasomotor symptoms remains the primary endpoint for dose adjustment, not serum estradiol concentration 3.